EUVIMEDEUVIMED entdecken
Systematische Übersicht

Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris

Syed Minhaj Rahman, Fahad Ahmed, Adel Haque

Archives of Dermatological Research · 2024

DOI: 10.1007/s00403-024-03137-3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Archives of Dermatological Research, 2024. Verfasst von Syed Minhaj Rahman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY, USA. minhaj_rahman@urmc.rocheste…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pityriasis Rubra Pilaris. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pityriasis rubra pilaris (PRP) is a rare and chronic inflammatory dermatologic condition characterized by hyperkeratotic salmon-colored plaques and palmoplantar keratoderma. Traditional therapeutic modalities have shown limited efficacy and often entail potential adverse effects, highlighting the need for alternative treatment options. Our review aims to summarize the current evidence on the off-label use of IL-23 inhibitors, risankizumab and guselkumab, in the treatment of PRP. These biologic agents have been approved for psoriasis, and their potential role in managing PRP has recently garnered interest. We conducted a comprehensive literature search on PubMed and Scopus databases, identifying relevant studies published in English up to June 2023 following PRISMA guidelines. A total of 10 studies were selected for data extraction and review. Results from the selected studies demonstrated encouraging outcomes with both risankizumab and guselkumab in managing PRP. Among 11 patients treated with risankizumab, 10 showed notable improvements in various disease manifestations, including pruritus, erythema, and affected body surface area. DLQI scores and BSA percentages reported a significant improvement before and after risankizumab treatment (p = 0.0322; p = 0.0216). However, two cases also reported symptom aggravation or even disease worsening. Patients treated with guselkumab exhibited ultimate improvement in all five cases, with complete clearance in three out of five cases. DLQI and BSA percentages also reported significant improvement with treatment with guselkumab (p = 0.0172; p < 0.0001). While most cases demonstrated positive outcomes, there were isolated instances of worsening symptoms, emphasizing the need for caution and further investigation. Further research with larger sample sizes and longer follow-up periods is necessary to establish the efficacy, optimal dosing, and long-term safety of risankizumab and guselkumab in treating PRP. Overall, we provide valuable insights into the potential use of IL-23 inhibitors, risankizumab, and guselkumab, as promising treatment options for PRP. These biologics have shown efficacy in improving symptoms in treatment-resistant cases, offering new avenues for clinicians to explore in the treatment of PRP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPityriasis Rubra PilarisHumansAntibodies, MonoclonalDermatologic AgentsInterleukin-23Off-Label UseTreatment Outcome

Stichwörter der Autor:innen

BiologicsGuselkumabInterleukin-23Pityriasis rubra pilarisRisankizumab

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatologic AgentsguselkumabInterleukin-23risankizumab

Autor:innen und Institutionen

  • Department of Dermatology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY, USA. minhaj_rahman@urmc.rochester.edu.
  • Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Dermatology Partners, Macungie, PA, USA.
  • Adjunct Professor of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
  • Adjunct Professor of Dermatology, University of New England College of Medicine, Biddeford, ME, USA.

Zitieren

APA

Rahman, S. M., Ahmed, F., & Haque, A. (2024). Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-03137-3

Vancouver

Rahman SM, Ahmed F, Haque A. Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris. Archives of Dermatological Research. 2024. doi:10.1007/s00403-024-03137-3

BibTeX
@article{Rahman2024,
  author = {Rahman, Syed Minhaj and Ahmed, Fahad and Haque, Adel},
  title = {Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris},
  journal = {Archives of Dermatological Research},
  year = {2024},
  doi = {10.1007/s00403-024-03137-3}
}
Kostenlos starten →